PACB - Pacific Biosciences of California Non-GAAP EPS of -$0.35 beats by $0.02 revenue of $27.35M beats by $0.06M
- Pacific Biosciences of California press release ( NASDAQ: PACB ): Q4 Non-GAAP EPS of -$0.35 beats by $0.02 .
- Revenue of $27.35M (-24.0% Y/Y) beats by $0.06M .
- Received record orders in the fourth quarter, including orders for 96 instruments, which included orders for 76 Revio systems from 43 customers across 13 countries and representing a broad set of applications.
- Instrument revenue of $6.1 million, compared with $16.2 million in the prior-year period.
- Consumables revenue of $16.7 million compared with $15.0 million in the prior year period. Sequel II and IIe consumables represented approximately 94% of our total consumable revenue in the fourth quarter of 2022, with the rest from older systems and other consumables.
- Service and other revenue of $4.6 million compared with $4.8 million in the prior year period.
For further details see:
Pacific Biosciences of California Non-GAAP EPS of -$0.35 beats by $0.02, revenue of $27.35M beats by $0.06M